Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]
This appeal hearing will hear appeals against the Final Appraisal Document for the above technology submitted by the following organisations:
- Fight Bladder Cancer
- Action Bladder Cancer UK
- Merck Serono Ltd
- British Uro-Oncology Group
- Association of Cancer Physicians
The appeal panel will convene on Tuesday 28 September 2021 from 10am on Zoom, to hear oral representation from the appellants.
This page was last updated: